OSE Immunotherapeutics Reveals 2025 Financial Results and 2026 Cash Position

OSE Immunotherapeutics reported its full year 2025 unaudited financial results, highlighting a €22.7 million cash position at the year's end, decreasing to €17.0 million by March 31, 2026. Operating income in 2025 plummeted to €2.7 million from €83.4 million the previous year, primarily due to the absence of significant non-recurring revenues from prior major licensing agreements.

Research and development costs rose to €33.9 million, driven by ongoing trials and reduced research tax credits. General and administrative expenses increased significantly to €8.8 million, partly due to exceptional legal fees. Operating loss reached €37.5 million, a stark contrast to the previous year's profit.

The company's cash is projected to sustain operations until early Q4 2026, as it explores strategic partnerships and financing options. The filing of the 2025 Universal Registration Document is delayed until May 28, 2026.